COSMETIC COMPOSITIONS COMPRISING A SENNOSIDE

Abstract

COSMETIC COMPOSITIONS COMPRISING A SENNOSIDE The present invention relates to cosmetic compositions comprising a compound of formula (I) as described below, and to their use for promoting and / or accelerating skin regeneration, for preventing and / or treating the signs of aging, and for promoting and / or accelerating wound healing. The invention also relates to cosmetic methods comprising the application of such compositions. Figure for abstract: none

Description

Title of the invention: COSMETIC COMPOSITIONS COMPRISING A SENNOSIDE

[0001] The present invention relates to cosmetic compositions comprising a compound of formula (I) as described below or an optical isomer thereof, or a cis-trans isomer thereof, or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof, such as a hydrate thereof, and their use for promoting and / or accelerating skin regeneration, for preventing and / or treating signs of aging, and for promoting and / or accelerating wound healing. The invention also relates to cosmetic methods comprising the application of such compositions.

[0002] Human skin is made up of two compartments: a deep compartment, the dermis, and a superficial compartment, the epidermis. The epidermis is in contact with the external environment and its role is to protect the body from dehydration and external chemical or mechanical aggressions.

[0003] Accelerated wound closure is an area of ​​intensive scientific research aimed at improving healing following skin injury or in skin whose barrier function is compromised. For example, the skin barrier may become unbalanced, for example, after a cosmetic procedure such as laser treatments and chemical peels, or in the presence of external aggressions, such as irritants (detergents, acids, bases, oxidants, reducing agents, concentrated solvents, toxic gases or fumes), mechanical stresses (friction, shocks, abrasion, tearing of the surface, projection of dust, particles, shaving or hair removal), thermal or climatic imbalances (cold, dryness, radiation), xenobiotics (undesirable microorganisms, allergens) or internal attacks such as psychological stress.Following such external aggressions, a healing process is triggered, aimed at quickly and completely restoring this barrier. This physiological process depends on complex biological mechanisms involving numerous molecules and enzymes.

[0004] There is a need for compositions which promote skin healing and, in particular, which accelerate skin healing.

[0005] The objective of the invention is therefore to propose a cosmetic composition which meets all these requirements.

[0006] The inventors have surprisingly discovered that natural molecules of formula (I) are capable of accelerating wound healing and are therefore potentially useful for skin regeneration.

[0007] The present application provides compositions for accelerating skin regeneration following skin injury or following a cosmetic procedure, for promoting healing following said skin injury and / or improving the effectiveness of cosmetic skin procedures. Use of the compositions will result in faster healing time and recovery from the procedure, resulting in a greater patient willingness to undergo cosmetic procedures.

[0008] Thus, the present invention relates to a cosmetic composition, comprising in a cosmetically acceptable medium: • at least one compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof, or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof, or a solvate thereof such as a hydrate thereof, and • at least one compound chosen from thickeners, preservatives, perfumes, bactericides, pigments, dyes, carbon and / or silicone or inorganic oils, waxes, fillers, emulsifiers, co-emulsifiers, UVA and / or UVB light protection agents also called UV filters, polymers, hydrophilic and lipophilic gelling agents.

[0009] For the purposes of the present invention, and unless otherwise indicated: • an “alkyl” radical is a saturated, linear or branched hydrocarbon radical, in particular C1-C6, preferably C1-C4; • a “(poly)(hydroxy)(Ci-C6)alkyl radical” denotes a C1-C6 alkyl radical, preferably a C1-C4 alkyl radical, optionally substituted by one or more hydroxy radicals, preferably substituted by 1 to 4 hydroxy groups, more particularly by 1 to 3 hydroxy groups; • a “sugar” radical is a monosaccharide or a disaccharide radical. Examples of sugar radicals are sucrose, glucose, galactose, ribose, fucose, maltose, fructose, mannose, arabinose, xylose or lactose; • a “monosaccharide” means a monosidic sugar comprising at least 5 carbon atoms of formula CX(H2O)X, x being an integer greater than or equal to 5, preferably x is greater than or equal to 6, in particular x is from 5 to 7, preferably x = 6; They may be of D or L configuration, and of alpha or beta anomer, as well as one of its salts or one of its solvates such as hydrates; • “disaccharide” means a disaccharide sugar which is a compound consisting of two oses linked together by O-osidic bonds, said compounds consisting of two monosaccharides (also called mono-osidics) as defined above, said monosaccharide units comprising at least 5 carbon atoms, preferably 6, in particular the monosaccharide units are linked together in 1,4 or 1,6, of alpha or beta anomer, each osidic unit being of L or D configuration, as well as one of its salts or its solvates such as hydrates. A disaccharide is more particularly a polymer formed from two oses (or monosaccharides) corresponding to the general formula: [Cx(H2O)y)]2 or [(CH2O)x]2, x being an integer greater than or equal to 5, preferably x is greater than or equal to 6, in particular x is from 5 to 7, preferably x = 6, and y is an integer which represents x-1; • by “mineral or organic salt” we mean the salt of bases or alkaline agents, such as alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, ammonia, amines, alkanolamines, or salts of so-called “basic” amino acids such as lysine or arginine.

[0010] Another object of the invention is the use of said compound or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvate thereof, or a composition according to the invention, for promoting and / or accelerating skin regeneration.

[0011] Another object of the invention is the use of said compound or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvate thereof, or a composition according to the invention, for preventing and / or treating the signs of aging.

[0012] Another object of the invention is the use of said compound or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvate thereof, or a composition according to the invention, for promoting and / or accelerating the healing of wounds.

[0013] The present invention also relates to a non-therapeutic method for treating the skin comprising the step of applying said at least one compound or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof, or a salt thereof, or a solvate thereof, or the composition according to the invention, to the skin.

[0014] Another object of the invention is a method of treating the skin to promote and / or accelerate the healing of wounds after aesthetic procedures, the method comprising: a. treatment of the skin with at least one skin-altering stimulus, and b. after step (a) applying a composition comprising a compound of formula (I), or an optical isomer thereof, or a cis-trans isomer of the latter (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvate thereof, on the skin.

[0015] Other subjects, characteristics, aspects and advantages of the invention will appear even more clearly on reading the description and the examples which follow.

[0016] Compositions

[0017] The composition according to the invention comprises at least one compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvate thereof such as a hydrate thereof: ntî Formula (I)

[0018] in which: • R' and R" are identical or different, preferably identical, and represent H or a monosaccharide or a polysaccharide comprising up to 20 sugar units, preferably up to 6 sugar units, in the form of pyranose and / or furanose and of L and / or D range, said mono- or polysaccharide may be substituted by a hydroxyl group which is obligatorily free, and optionally one or more amine functions, optionally one or more protected amine functions, and said monosaccharide or polysaccharide being optionally substituted on its CH2OH group by a -C(O)-CO2H group; • R represents H or -C-(O)-O-Ri or -Alk-X-Ri, preferably -C-(O)-OR i or Alk-O-Ri, X being O, S or -NR1, preferably O; Ri being H or a saturated or unsaturated hydrocarbon chain, preferably saturated in C1-C6, more preferably Ri corresponds to H, and Alk corresponds to a C1-C6 alkylene group, preferably -CH2-.

[0019] Advantageously, R' and R" are identical or different and represent a monosaccharide or a polysaccharide containing up to 6 sugar units, in the form of pyranose and / or furanose and of L and / or D range, said mono- or polysaccharide having at least one hydroxyl function which is obligatorily free and / or optionally one or more amine functions which are obligatorily protected.

[0020] Advantageously, the monosaccharide is chosen from D-glucose, D-galactose, D-mannose, D-xylose, D-lyxose, L-fucose, L-arabinose, L-rhamnose, D-glucuronic acid, D-galacturonic acid, D-iduronic acid, N-acetyl-D-glucosamine and N-acetyl-D-galactosamine. Monosaccharide advantageously denotes D-glucose, L-rhamnose, D-xylose, N-acetyl-D-glucosamine or L-fucose, and more preferably D-glucose.

[0021] Advantageously, the polysaccharide containing up to 6 sugar units may be chosen from D-maltose, D-lactose, D-cellobiose, D-maltotriose, a disaccharide combining a uronic acid chosen from D-iduronic acid or D-glucuronic acid with a hexosamine chosen from D-galactosamine, D-glucosamine, N-acetyl-D-galactosamine, N-acetyl-D-glucosamine, a disaccharide combining L-rhamnose and D-galactose, an oligosaccharide containing at least one xylose which may be advantageously chosen from xylobiose, methyl-[3-xylobioside, xylotriose, xylotetraose, xylopentaose and xylohexaose and particularly, xylobiose which is composed of two xylose molecules linked by a 1-4 bond.

[0022] More preferably, R' and R" are identical and represent a monosaccharide chosen from D-glucose, D-xylose, L-fucose, L-rhamnose, D-galactose and D-maltose, preferably D-glucose.

[0023] The monosaccharide or polysaccharide of R' and / or R" may be substituted on one or more hydroxymethyl residues by a -C(O)-COOH group.

[0024] Advantageously, said compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvate thereof such as a hydrate thereof, is in the form of a plant extract.

[0025] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof such as a hydrate thereof, is chosen from sennosides A, B, C, D, E and F, preferably it is chosen from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0026] The compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof such as a hydrate thereof, preferably Sennoside A or one of its salts, is present in solubilized form in the composition. By “in solubilized form” is meant that the compound does not form crystals visible to the naked eye in the composition.

[0027] Sennoside A (C42H3802o) (or (97?)-9-[(97?)-2-carboxy-4-hydroxy-10-oxo-5-[(25, 3R, 45,55,67?)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9 7 / -anthracen-9-yl]-4-hydroxy-10-oxo-5-[(25,37?,45,55,67?)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9 / / -anthracene-2-carboxylic acid in IUP name AC) has the CAS number 81-27-6 and is of formula (I'). m Formula (I')

[0028] Sennoside, and preferably sennoside A, may also be present in salt form.

[0029] By "salt" is meant a cosmetically acceptable salt, i.e. a salt which is compatible with application to the skin, mucous membranes and / or appendages. The salt of the compound of formula (I), preferably the sennoside A salt, may be an alkali or alkaline earth metal salt, preferably a calcium, magnesium, sodium or potassium salt.

[0030] Typically, the salt of the compound of formula (I), preferably the sennoside salt such as sennoside A salt, may exist once the compound has been introduced into the composition. In fact, the compound of formula (I) is introduced into the composition in unsalified form.

[0031] Preferably, the composition comprises a sennoside A, for example sennoside A marketed by INTERCHIM under the name Sennoside A.

[0032] Preferably, the composition comprises a mixture of sennosides containing at least sennoside A.

[0033] Preferably, the composition comprises between 0.01% and 5% by weight relative to the total weight of the composition, more preferably between 0.2 and 4%, even more preferably between 0.3 and 3%, or between 0.4 and 1% by weight relative to the total weight of the composition of the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof such as a hydrate thereof.

[0034] Preferably, the composition comprises between 0.1 and 5% by weight of sennoside A or one of its salts relative to the total weight of the composition, preferably between 0.2 and 4% by weight, more preferably between 0.3 and 3% by weight, most preferably between 0.4 and 1% by weight.

[0035] Unless otherwise stated, the percentages are expressed by weight of the total weight of the composition.

[0036] Finally, the composition according to the invention comprises ingredients usual in the cosmetic field.

[0037] The composition according to the invention comprises at least one compound chosen from thickeners, preservatives, perfumes, bactericides, pigments, dyes, carbon and / or silicone or inorganic oils, waxes, fillers, emulsifiers, co-emulsifiers, UVA and / or UVB light protection agents also called UV filters, polymers, hydrophilic and lipophilic gelling agents. The person skilled in the art can adjust the type and quantity of these ingredients in the compositions according to the invention by means of routine operations, so that the desired cosmetic properties and stability properties of these compositions are not adversely affected. The amounts of these various ingredients are conventionally the amounts used in the particular field, for example from 0.01% to 20% of the total weight of the composition.

[0038] In one embodiment, the composition of the invention further comprises one or more cutaneous active agents chosen from anti-aging agents and wound healing agents.

[0039] The term "anti-aging agents" designates all cosmetic agents known to those skilled in the art suitable for reducing and / or slowing the progression of signs of aging of the skin such as marked micro-relief of the skin, fine lines, the appearance of wrinkles, loss of tone, loss of density, loss of firmness, loss of elasticity, reduction in the thickness of the dermis and / or the epidermis, dryness, sagging skin, loss of radiance of the complexion, the appearance of a dried-out appearance of the skin, sagging of the skin, sagging of the skin and loss of the skin's ability to regenerate.

[0040] The expression “wound healing agents” designates any cosmetic agent known to those skilled in the art suitable for promoting and / or accelerating the healing of wounds.

[0041] The one or more active skin agents may be included in the cosmetic composition in an amount ranging from 0.001% to 5% by weight relative to the total weight of the composition, more preferably between 0.01 and 2%, even more preferably between 0.02 and 1%, or between 0.05 and 1% by weight relative to the total weight of the composition.

[0042] In another embodiment, the composition of the invention comprises only the at least one compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof, or a solvate thereof such as a hydrate thereof, as a cutaneous active agent.

[0043] The composition according to the invention comprises a cosmetically acceptable medium.

[0044] Here, "cosmetically acceptable medium" means a non-toxic support which can be applied to keratinous materials such as the skin and mucous membranes. Thus, a cosmetically acceptable medium is compatible with the skin, the integuments and / or the mucous membranes, it does not induce any sensation of discomfort, or more generally any disorder likely to cause the user to suspend or stop the administration of the cosmetic composition.

[0045] More particularly, said cosmetically acceptable medium may comprise water and / or one or more water-miscible organic solvents. Said solvent may be chosen from polyols and alcohols, such as glycerin, sorbitol, glycols such as butylene glycol, propylene glycol, isoprene glycol, dipropylene glycol, hexylene glycol, polypropylene glycol, ethanol or propanediol.

[0046] Preferably, the composition according to the invention has a water content ranging from 20% to 95% by weight, more preferably from 30% to 70% by weight relative to the total weight of the composition.

[0047] A composition according to the invention may comprise an oily phase.

[0048] The compositions according to the invention can have all dosage forms conventionally used for topical application and in particular in the form of aqueous solutions, hydroalcoholic solutions, oil-in-water (O / W) or water-in-oil (W / O) emulsions or multiple (triple: / W or O / W / O) emulsions, aqueous gels, or dispersions of an oily phase in an aqueous phase using spheres, these spheres potentially being lipid vesicles of ionic and / or non-ionic type (liposomes, niosomes, oleosomes). These compositions are prepared using routine methods.

[0049] The cosmetic compositions of the present disclosure are preferably stable. The term "stable" as used herein means that the cosmetic composition does not visually separate phases or crystallize and does not completely degrade.

[0050] In a preferred embodiment, the compositions used in the context of the invention are intended for topical administration. In a preferred embodiment, the compositions used in the context of the invention are intended to be applied to the skin.

[0051] In the context of the invention, the term "skin" designates any cutaneous surface of the body, preferably the skin of the face or neck or legs, and more particularly the skin of the face or neck.

[0052] Advantageously, the compositions according to the invention have the form of a gel, or an emulsion, a powder or a paste. In addition, the composition according to the invention may be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foaming gel, a scrub, a mask, a treatment, a tonic or a mousse.

[0053] The compositions according to the invention may be applied directly to the skin or, alternatively, to cosmetic supports of the occlusive or non-occlusive type, intended to be applied locally to the skin. As non-limiting examples of cosmetic supports, mention may be made of a dressing, a wipe, a mask on a support. The composition may or may not be rinsed after being applied to the skin, preferably it is not rinsed.

[0054] Uses

[0055] The present invention also relates to the use of at least one compound of formula (I) as described herein or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof such as a hydrate thereof, for promoting and / or accelerating skin regeneration.

[0056] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof such as a hydrate thereof, is chosen from sennosides A, B, C, D, E and F, preferably it is chosen from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0057] The present invention also relates to the use of a composition according to the invention, to promote and / or accelerate skin regeneration.

[0058] Skin regeneration is the innate ability of living organisms to repair their skin, through a healing process. In the context of the invention, skin regeneration may follow skin injury, skin whose barrier function is compromised, for example, during or after cosmetic surgery procedures.

[0059] Here, the term "promote" refers to increasing the effects of the phenomenon. For example, promoting skin regeneration may lead to greater skin generation than without the use according to the invention.

[0060] Here, the term "accelerate" refers to accelerating the phenomenon. For example, accelerating skin regeneration may result in the same amount of regenerated skin but in less time than without the use according to the invention.

[0061] The present invention relates to the use of at least one compound of formula (I) as described herein or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof such as a hydrate thereof, according to the invention, for preventing and / or treating the signs of aging.

[0062] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof such as a hydrate thereof, is chosen from sennosides A, B, C, D, E and F, preferably it is chosen from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0063] The present invention relates to the use of the composition according to the invention, for preventing and / or treating the signs of aging.

[0064] Here, the term "prevent" or "prevention" designates any action aimed at preventing the appearance of discomfort or inconvenience in an individual. This term therefore covers the stopping or limitation of symptoms, but is limited to cosmetic aspects.

[0065] Here, the term "treat" or "treatment" means any action aimed at improving the comfort or well-being of an individual. This term therefore covers the alleviation, slowing down, easing or suppression of symptoms, but is limited to cosmetic treatment.

[0066] The expression "signs of aging" herein designates all the changes that occur in a subject with age. Preferably, the signs of aging according to the invention are signs of aging of the skin.

[0067] The term "signs of skin aging" or "signs of skin aging" herein refers to all changes in the skin that occur with age and are sometimes not visible at an early stage. Signs of skin aging include marked micro-relief of the skin, fine lines, the appearance of wrinkles, loss of tone, loss of density, loss of firmness, loss of elasticity, reduction in the thickness of the dermis and / or epidermis, dryness, sagging skin, loss of radiance of the complexion, the appearance of a dried-out appearance of the skin, sagging of the skin, sagging of the skin and loss of the skin's ability to regenerate.

[0068] The present invention relates to the use of at least one compound of formula (I) as described herein or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof such as a hydrate thereof, for promoting and / or accelerating the healing of wounds.

[0069] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof such as a hydrate thereof, is chosen from sennosides A, B, C, D, E and F, preferably it is chosen from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0070] The present invention relates to the use of a composition according to the invention, to promote and / or accelerate the healing of wounds and in particular the healing of skin wounds.

[0071] Wound healing is the innate ability of living organisms to heal from a wound, through a healing process. In the context of the invention, skin regeneration may follow a skin lesion or a skin wound.

[0072] Preferably, the uses according to the invention are topical uses. Preferably, the composition is applied to the skin, more preferably to the face, legs or body, more preferably to the face.

[0073] Methods

[0074] The invention relates to a non-therapeutic, preferably cosmetic, method for treating the skin comprising the step of applying the composition according to the invention to the skin.

[0075] Preferably, the step of applying the composition is carried out by the topical application of said composition, more preferably on the face, legs or body, more preferably on the face or neck.

[0076] Preferably, the skin exhibits at least one sign of skin aging as defined above.

[0077] Preferably, the application is carried out on the skin of a subject in need thereof and in an effective amount of the composition. Here, the term "subject" means a human being.

[0078] Preferably, the subject does not suffer from a dermatological lesion and / or dermatological disease, more preferably the subject does not suffer from any disease.

[0079] Here, the expression “effective amount” refers to the amount of composition according to the invention, which, as a whole, makes it possible to: • promote and / or accelerate skin regeneration, and / or • prevent and / or treat the signs of aging, and / or • promote and / or accelerate wound healing.

[0080] According to the present invention, the methods are non-therapeutic methods.

[0081] The methods of the invention may comprise a single administration. In another embodiment, the administration is repeated, for example, 2 to 3 times per day for one day or more and generally for an extended period of at least 4 weeks or 4 to 15 weeks, or as long as necessary.

[0082] The invention also relates to a non-therapeutic, preferably cosmetic, method of treating the skin to promote and / or accelerate the healing of wounds after aesthetic procedures, the method comprising: a. treatment of the skin with at least one skin-altering stimulus, and b. after step (a) applying a composition comprising a compound of formula (I), or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvate thereof according to the invention to the skin.

[0083] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof such as a hydrate thereof, is chosen from sennosides A, B, C, D, E and F, preferably it is chosen from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0084] In still other embodiments, the non-therapeutic, preferably cosmetic method according to the invention comprises: a. treatment of the skin with at least one type of skin-altering stimulus, e.g., a peeling agent, laser, radiofrequency, electrical energy, heat, low-level light, needle, or abrasive instrument; and b. after step (a) applying a composition comprising a compound of formula (I), or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvate thereof, according to the invention to the skin, in particular within about 6 hours after step (a).

[0085] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular an inorganic or organic salt thereof or a solvate thereof such as a hydrate thereof, is chosen from sennosides A, B, C, D, E and F, preferably it is chosen from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0086] By "skin modifying stimulus" is meant an action on the skin that will induce a modification of the skin, such stimulus being able to temporarily compromise the barrier function of the skin. For example, the skin modification includes a peeling agent, a laser, a radio frequency, an electrical energy, heat, a low level light, a needle or an abrasive instrument.

[0087] The invention also relates to a non-therapeutic, preferably cosmetic, method of treating the skin to promote and / or accelerate the healing of wounds after aesthetic procedures, the method comprising: a. treatment of the skin with at least one skin-altering stimulus, and b. after step (a) applying a composition according to the invention to the skin.

[0088] In still other embodiments, the method of the invention comprises: a. treating the skin with at least one type of skin-altering stimulus, e.g., a peeling agent, a laser, radiofrequency, electrical energy, heat, low-level light, a needle, or an abrasive instrument; and b. after step (a) the application of a composition according to the invention to the skin, in particular within approximately 6 hours after step (a). Brief description of the drawings

[0089] [Fig-1] [Fig.l]: Acceleration of wound closure in reconstructed skin in 3D. Treatment of full-thickness reconstructed skin starting on day 10 after the start of reconstruction resulted in a statistically significant acceleration of wound closure at day 14, as determined by OCT. Data represent box plots. ** represents p<0.01, one-way ANOVA, n=6, representative of 3 independent experiments.

[0090] [Fig.2] [Fig.2]: Acceleration of wound closure in 3D reconstructed skin. Treatment of full-thickness reconstructed skin starting on day 10 after the start of reconstruction resulted in a statistically significant acceleration of wound closure at day 15, as determined by OCT. Data represent box plots. ** represents p<0.01, one-way ANOVA, n=6, representative of 3 independent experiments. Example#: Materials and Processes

[0091] Organotypic healing of 3D reconstructed skin wounds

[0092] Reconstructed T-skin models were constructed as previously described (Bataillon, et al., Characterization of a New Reconstructed Full Thickness Skin Model, T-SkinTM, and its Application for Investigations of Anti-Aging Compounds. Int J Mol Sci. 2019 May;20(9)). Briefly, keratinocytes and fibroblasts were isolated from skin biopsies. A ring was placed on the surface of the epidermis that would prevent keratinocyte coverage of this area, providing an area of ​​exposed collagenized dermis and simulating a partial-thickness wound. At day 10, The ring was removed and the wound treated with either an indicated raw material or a control vehicle of 1 / 1000 DMSO in PBS. The wound was treated every three days. Oncostatin (10 ng / mL) and vitamin C (100 pg / mL) were used as positive controls. The closure rate was determined by optical coherence tomography (OCT) to monitor wound closure. The closure rate is expressed as the percentage increase in closure compared to that of the control. Data are presented as box plots with 3 replicates per condition in Figures 1 and 2. Statistical analysis was done using one-way ANOVA with post-hoc analysis and Levene's test for homogeneity of variance. Data are representative of three independent experiments. RESULTS

[0093] The compound of formula (I) accelerates wound healing in an organotypic 3D reconstructed skin model

[0094] A wound healing model was used to determine the ability of sennoside A (50 pM) to accelerate wound closure over a twenty-day period. The two positive controls Oncostatin M (2 ng / mL) and Vitamin C (100 pg / mL) accelerated wound closure on days 14 ([Fig.l]) and 15 ([Fig.2]), as expected. Similarly, sennoside accelerated wound closure. These data demonstrate that sennoside can accelerate the healing and regeneration of cutaneous wounds. CONCLUSION

[0095] These data demonstrate that a compound of formula (I) results in wound closure in a 3D reconstructed skin healing model. The invention therefore has clear indications for use in skin regeneration, wound healing, promoting skin healing following a surgical / cosmetic procedure and associated skin health outcome indicators requiring modulation of skin cells.

Claims

1. Claims Cosmetic composition, comprising in a cosmetically acceptable medium: - at least one compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof, or a tautomer thereof or a salt thereof, or a solvate thereof, R'"- OO OH in which: - R' and R" are identical or different, preferably identical, and represent H or a monosaccharide or a polysaccharide comprising up to 20 sugar units, preferably up to 6 sugar units, in the form of pyranose and / or furanose and of L and / or D range, said mono- or polysaccharide may be substituted by a hydroxyl group which is obligatorily free, and optionally one or more amine functions, optionally one or more protected amine functions, and said monosaccharide or polysaccharide being optionally substituted on its CH2OH group by a -C(O)-CO2H group; - R represents H or -C-(O)-O-Ri or -Alk-X-Ri, preferably -C-(O)-O-Ri or Alk-O-Ri, X being O, S or -NR1, preferably O; Ri being H or a saturated or unsaturated hydrocarbon chain, preferably saturated in C1-C6, more preferably Ri corresponds to H, and Alk corresponds to a C1-C6 alkylene group> preferably -CH2-; And ; - at least one compound chosen from thickeners, preservatives, perfumes, bactericides, pigments, dyes, carbon and / or silicone or inorganic oils, waxes, fillers, emulsifiers, co-emulsifiers, UVA and / or UVB light protection agents also called UV filters, polymers, hydrophilic and lipophilic gelling agents.

2. A composition according to claim 1, wherein said compound is a sennoside.

3. A composition according to claim 2, wherein said sennoside is sennoside A, B, C, D, E, F, an enantiomer thereof, or a cis-trans isomer thereof.

4. Composition according to any one of claims 1 to 3 further comprising one or more skin active agents chosen from anti-aging agents and wound healing agents.

5. Composition according to any one of claims 1 to 4, characterized in that the concentration of said at least one compound of formula (I) is between 0.01% and 5% by weight relative to the total weight of the composition.

6. A compound of formula (I) according to claim 1, or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvate thereof, for preventing and / or treating the signs of aging.

7. Composition according to any one of claims 1 to 5, for preventing and / or treating the signs of aging.

8. A compound according to claim 6, wherein the signs of aging are signs of skin aging.

9. A non-therapeutic method of treating the skin, comprising applying the composition according to any one of claims 1 to 5 to the skin.

10. The method of claim 9, wherein the skin exhibits at least one sign of skin aging.

Images